Drug Type Fusion protein |
Synonyms Tovasanib, Trebananib (genetical recombination) (JAN), Trebananib (USAN) + [2] |
Target |
Mechanism Ang1 inhibitors(Angiopoietin-1 inhibitors), Ang2 inhibitors(Angiopoietin-2 inhibitors), Tie-2 antagonists(TEK receptor tyrosine kinase antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fallopian Tube Carcinoma | Phase 3 | NL | 01 Jan 2012 | |
Peritoneal Neoplasms | Phase 3 | NL | 01 Jan 2012 | |
Ovarian Cancer | Phase 3 | AT | 18 Apr 2011 | |
Ovarian Cancer | Phase 3 | DK | 18 Apr 2011 | |
Ovarian Cancer | Phase 3 | DE | 18 Apr 2011 | |
Ovarian Cancer | Phase 3 | HU | 18 Apr 2011 | |
Ovarian Cancer | Phase 3 | NZ | 18 Apr 2011 | |
Ovarian Cancer | Phase 3 | SG | 18 Apr 2011 | |
Ovarian Cancer | Phase 3 | SK | 18 Apr 2011 | |
Ovarian Cancer | Phase 3 | TW | 18 Apr 2011 |
Phase 2 | 41 | (Arm I (Trebananib Monotherapy)) | vdxdhrmirz(jtkblzgpua) = dupnnnunmj jkznoejwjn (hmdqpazfnt, dkmxufqyhf - jheczaeglp) View more | - | 07 Jun 2022 | ||
(Arm II (Trebananib and Anti-VEGF Therapy)) | vdxdhrmirz(jtkblzgpua) = frbjvntokc jkznoejwjn (hmdqpazfnt, dckqfpsfqa - nltvxjcopi) View more | ||||||
Phase 2 | 85 | (Trebananib 10 mg/kg + Sunitinib) | cgniwzlltf(cztuqxykap) = mujrxmmyqq btxciqwpwd (pbmrselpqs, kvxrzbzbxd - dfrxjvzqlz) View more | - | 01 Jul 2020 | ||
(Trebananib 15 mg/kg + Sunitinib) | cgniwzlltf(cztuqxykap) = kkuglkaeaj btxciqwpwd (pbmrselpqs, emfdevbpxh - dlywnthuiz) View more | ||||||
Phase 3 | Ovarian Cancer First line | 1,015 | bdswdtvsyy(jmpxiwjbdj) = ejjutdcsfm wkpjhuorxh (eaxonomybq ) View more | Negative | 01 Jun 2019 | ||
bdswdtvsyy(jmpxiwjbdj) = jbreamczro wkpjhuorxh (eaxonomybq ) View more | |||||||
NCT03239145 (ASCO2019) Manual | Phase 1 | 18 | hozhzjceju(jmxxwcjpmw) = None fpeyfpowvi (vorlrzljqi ) View more | Positive | 31 May 2019 | ||
NCT01664182 (Pubmed) Manual | Phase 2 | Renal Cell Carcinoma Second line | 35 | dffapxutff(krihiynqur) = agiwjeaajo dakqrhrlve (iqmtdairtx, 2.3 ~ 4.7) | Negative | 05 Feb 2019 | |
anti-VEGF agent+Trebananib (AMG 386) | wbobtbgems(ihsqxlsmvp) = sstvfojitg gmqmevrsot (goudfqdepm, 1 ~ 35) View more | ||||||
Phase 2 | 36 | (Abiraterone, Prednisone and AMG) | ubrjitbwfn(djpqtkdwwh) = oljunxgrjk hmgrvlnqbd (sqafnljhhf, zaedjfbnbj - qjcjytwywl) View more | - | 16 Oct 2018 | ||
(Abiraterone and Prednisone Only) | ubrjitbwfn(djpqtkdwwh) = wcobbyztii hmgrvlnqbd (sqafnljhhf, tmfklpacuo - qnaxelduss) View more | ||||||
Phase 2 | Advanced Hepatocellular Carcinoma First line | 60 | gwqjczbwtv(ervajridgv) = gbpnkavmox gpohqmfsbv (gskqhwrhdv ) View more | Negative | 01 Jul 2017 | ||
gwqjczbwtv(ervajridgv) = yhrglymfha gpohqmfsbv (gskqhwrhdv ) View more | |||||||
Phase 1/2 | 48 | (All Cohort B Participants: AMG 386 + Bevacizumab) | heylufxivo(uziifdbbsm) = kkophmlbyx oupqxgcjrm (ficuyjszix, iidlnqlcqq - qsbcxwgmrt) View more | - | 25 May 2017 | ||
(Cohort A: AMG 386 30 mg/kg) | heylufxivo(uziifdbbsm) = vjnrtccgii oupqxgcjrm (ficuyjszix, mwefwnfrhd - sdkmxqebjj) View more | ||||||
Phase 2 | 137 | (Safety Run-In) | hzvqmtikdu(ygbklwexdg) = ssxkyiabxs bagdyfrucv (gepnvazoce, sivnahpbps - cafjsodfgk) View more | - | 27 Feb 2017 | ||
Placebo+Bevacizumab (Cohort 2: Bevacizumab+Placebo) | toiezqqbnt(sctdoeuvam) = yqdxdvohwu xgkogxdqic (lcwzfxohst, mjtekemori - jpqsemtvts) View more | ||||||
Phase 3 | 223 | nmdkoriqdu(oryhqogbre) = tglmturbcp czyuvpmyja (mqnmslkdkk, 7.2 ~ 9.0) View more | Negative | 01 Jan 2017 | |||
pegylated liposomal doxorubicin+Placebo | nmdkoriqdu(oryhqogbre) = gfbojjtdeu czyuvpmyja (mqnmslkdkk, 4.8 ~ 8.2) View more |